Search

Displaying results 2731 - 2740 of 10000 in total
  1. Drug

    Prasugrel

    go.drugbank.com/drugs/DB06209
    ApprovedInvestigational

    FDA approved in 2009. … Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary

  2. Drug

    Candicidin

    go.drugbank.com/drugs/DB01152
    ApprovedInvestigationalWithdrawn

    Candicidin is administered intravaginally in the treatment of vulvovaginal candidiasis. … Candicidin is an antibiotic obtained from a streptomyces (Streptomyces griseus) and active against some fungi of the genus Candida (C. albicans).

  3. Drug

    Teriflunomide

    go.drugbank.com/drugs/DB08880
    ApprovedInvestigational

    It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. … Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis.

  4. Drug

    Streptococcus pneumoniae type 7F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10297
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 7F capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae

    Mixtures: PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, 10 ADET
  5. Drug

    Streptococcus pneumoniae type 19A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10298
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 19a capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae

    Mixtures: PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, 10 ADET
  6. Drug

    Dithiazanine

    go.drugbank.com/drugs/DB11516
    ApprovedVet approvedWithdrawn

    Dithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032] … Dithiazanine is a highly potent anthelmintic, introduced in 1959 for the treatment of strongyloid worms and whipworms. However, its use is severely limited due to its toxicity.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Fingolimod

    go.drugbank.com/drugs/DB08868
    ApprovedInvestigational

    It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus. … [A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis.

  8. Drug

    Equine Botulinum Neurotoxin F Immune FAB2

    go.drugbank.com/drugs/DB13901
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients. … Equine Botulinum Neurotoxin F Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype F.

  9. Drug

    Streptococcus pneumoniae type 5 capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10295
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 5 capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae*

    Mixtures: PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, 10 ADET
  10. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    [L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from